How α6β4 Integrin Affects Tamoxifen Resistance in Breast Cancer
Author Information
Author(s): Folgiero Valentina, Avetrani Paolo, Bon Giulia, Di Carlo Selene E., Fabi Alessandra, Nisticò Cecilia, Vici Patrizia, Melucci Elisa, Buglioni Simonetta, Perracchio Letizia, Sperduti Isabella, Rosanò Laura, Sacchi Ada, Mottolese Marcella, Falcioni Rita
Primary Institution: Regina Elena Cancer Institute, Rome, Italy
Hypothesis
The study investigates the role of α6β4 integrin and ErbB-3 in the resistance to Tamoxifen in ERβ1-negative breast cancer.
Conclusion
The study found a significant relationship between α6β4 and ErbB-3 in ERβ1-negative breast cancers, indicating their relevance in predicting Tamoxifen response.
Supporting Evidence
- α6β4 integrin expression is associated with ErbB-3 positivity in breast cancer.
- Depletion of ErbB-3 leads to increased apoptosis in breast cancer cells.
- Patients with ERβ1-negative tumors have lower disease-free survival rates.
Takeaway
This study shows that a protein called α6β4 helps another protein, ErbB-3, which can make breast cancer harder to treat with a common medicine called Tamoxifen.
Methodology
The study used human breast cancer cell lines and analyzed 232 breast cancer biopsies to evaluate the interaction between α6β4 and ErbB-3 in relation to Tamoxifen responsiveness.
Limitations
The expression of α6β4 did not directly influence patient outcomes, indicating other factors may also play a role.
Participant Demographics
{"mean_age":63,"menopausal_status":{"pre":25,"post":207},"histotype":{"invasive_ductal_carcinoma":193,"invasive_lobular_carcinoma":28,"tubular_carcinoma":7,"papillary_carcinoma":4}}
Statistical Information
P-Value
p<0.0001
Confidence Interval
C.I. 1.90–13.32
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website